- Title
- Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry
- Creators
- A. Oliver Sartor - Tulane Medical School, New Orleans, LACelestia S. Higano - University of WashingtonMatthew R. Cooperberg - University of California, San FranciscoNicholas J. Vogelzang - Comprehensive Cancer Centers of NevadaShaker R. Dakhil - Wichita ClinicChristopher Michael Pieczonka - Associated Medical Professionals of New York, PLLC, Syracuse, NYJeff Vacirca - New York Cancer and Blood Specialists, New York, NYRaoul S Concepcion - Urology AssociatesRonald F Tutrone - Chesapeake Urology AssociatesLuke T. Nordquist - Urology Cancer Center and GU Research NetworkCarl A Olsson - Columbia University Irving Medical CenterDavid F. Penson - Vanderbilt University Medical CenterIan Schnadig - Compass OncologyJames L. Bailen - First Urology Research, Louisville, KYBryan Mehlhaff - Oregon Urology InstituteNancy N. Chang - Dendreon (United States)Nadeem Anwar Sheikh - Dendreon (United States)Bruce Brown - Dendreon (United States)Andrew J. Armstrong - Duke Medical Center
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5041-5041
- Identifiers
- 991006262540602656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry
Journal of clinical oncology, Vol.36(15_suppl), pp.5041-5041
05/20/2018
Metrics
1 Record Views